Close Menu

skin cancer

Researchers from the British Columbia Cancer Agency this week presented results from a clinical study in which Verisante Technology's Raman spectroscopy-based Core device distinguished between cancerous and benign lung lesions with sensitivity and specificity of more than 90 perc

The device, named the Verisante Aura, uses Raman spectroscopy to measure levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions. In initial clinical trials it distinguished between benign and malignant lesions with 100-percent sensitivity and 70-percent specificity.

In addition to a five-marker diagnostic test that the company plans to launch in the second half of 2011, Myriad is developing a second melanoma test that would gauge survival benefit.

GSK is conducting a Phase III study for a MAGE-A3-targeting therapeutic for the adjuvant treatment of melanoma. To receive the drug in the study, participants' tumors must be shown to express MAGE-A3 via a molecular test that Abbott is developing.

Abbott and GSK will develop and commercialize a PCR test for the MAGE-A3 biomarker using Abbott's m2000 automated real-time PCR system.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.